BETALIN 12
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BETALIN 12 (BETALIN 12).
Betamethasone valerate is a corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
| Metabolism | Metabolized primarily in the liver via CYP3A4 to inactive metabolites; also undergoes extrahepatic metabolism in skin. |
| Excretion | Primarily renal (60-80% as unchanged drug), with minor biliary/fecal elimination (15-20%) and negligible metabolism. |
| Half-life | Approximately 2-3 hours in healthy adults; prolonged to 6-10 hours in renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | 25% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive extravascular distribution exceeding total body water. |
| Bioavailability | Oral: 70-85% (with minimal first-pass effect); IM: 90-95%. |
| Onset of Action | Oral: 1-2 hours; intravenous (IV): 5-10 minutes; intramuscular (IM): 15-30 minutes. |
| Duration of Action | Oral: 6-8 hours; IV/IM: 4-6 hours; effects correlate with plasma concentrations above 1 mcg/mL. |
1 mg intramuscularly once daily for 7 days, then 1 mg intramuscularly once weekly for 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients. |
| Geriatric use | No specific dose adjustment; use with caution due to potential for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BETALIN 12 (BETALIN 12).
| Breastfeeding | Excreted in human breast milk; M/P ratio not reported. Use with caution; monitor infant for signs of beta-blockade (bradycardia, hypoglycemia). |
| Teratogenic Risk | Pregnancy Category C. First trimester: No well-controlled studies; avoid use unless benefit outweighs risk. Second and third trimesters: Possible association with transient neonatal cardiomyopathy; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to betamethasone valerate or any component of the formulation.","Viral (e.g., herpes simplex, varicella), fungal, or bacterial skin infections without appropriate antimicrobial therapy.","Ophthalmic use (for topical dermatologic preparations)."]
| Precautions | ["Topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, or occlusive dressings.","Systemic absorption may manifest as Cushing's syndrome, hyperglycemia, or glucosuria.","Local adverse effects include atrophy, striae, telangiectasias, and perioral dermatitis.","Use with caution in patients with impaired skin barrier or on face, intertriginous areas."] |
| Food/Dietary | No significant food interactions. Absorption of oral B12 may be reduced by alcohol, metformin, proton pump inhibitors, and H2 blockers. Do not take with hot liquids as heat may degrade cyanocobalamin. High-dose vitamin C may reduce B12 availability if taken simultaneously. |
Loading safety data…
| Monitor maternal heart rate and blood pressure, fetal growth and heart rate by ultrasound if used chronically. Assess for signs of intrauterine growth restriction. |
| Fertility Effects | No known significant effect on fertility in humans; theoretical risk from hemodynamic changes. |
| Clinical Pearls | Cyanocobalamin (BETALIN 12) is a synthetic form of vitamin B12 used for deficiency. For pernicious anemia, intramuscular administration is preferred due to lack of intrinsic factor. Monitor serum B12, homocysteine, and methylmalonic acid levels. Sublingual tablets may be effective for mild deficiency if absorption intact. Avoid use in suspected cobalt allergy. High doses may cause hypokalemia in initial treatment of severe megaloblastic anemia due to rapid cell turnover. |
| Patient Advice | Take exactly as prescribed; do not exceed recommended dose. · For oral tablets, swallow whole with water; do not crush or chew. · Sublingual tablets: place under tongue until dissolved; avoid swallowing immediately. · Notify your doctor if you experience symptoms of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing). · Regular blood tests are needed to monitor B12 levels and response. · Do not take folic acid alone to treat B12 deficiency as it may mask worsening neurological symptoms. · Inform your doctor of all medications and supplements you take. · If you have kidney disease or low potassium levels, extra monitoring may be required. |